Kamada is a biopharmaceutical company specializing in plasma-derived protein therapeutics and related specialty biologics. Its portfolio is known for products such as treatments linked to alpha-1 antitrypsin deficiency and other niche plasma protein indications. The company serves patients and healthcare systems that need specialized, often limited-supply biologic therapies rather than mass-market primary care drugs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 44 | — | 4 | 71.1% |
| Q2 2025 | 44.8 | — | 7.4 | 59.1% |
| Q3 2025 | 47 | — | 5.3 | 31.6% |
| Q4 2025 | 44.7 | — | 3.6 | -11.5% |
| Q1 2026 | 45.2 | 2.8% | 4.1 | 4.2% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Obook Holdings Inc. (OWLS), Canopy Growth Corporation (CGC), TAT Technologies Ltd. (TATT), Johnson Outdoors Inc. (JOUT), Puma Biotechnology, Inc. (PBYI), Editas Medicine, Inc. (EDIT)